In line with the ongoing debate on the underlying mechanisms of Alzheimer’s disease (Seeley et al., 2009; Zhou et al., 2012), our findings shed some light on which networks are preferentially targeted by amyloid-β and tau as well as their clinical value in distinguishing different disease stages and predicting cognitive decline. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.